AU1763892A - New non-anticoagulant heparin derivatives - Google Patents

New non-anticoagulant heparin derivatives

Info

Publication number
AU1763892A
AU1763892A AU17638/92A AU1763892A AU1763892A AU 1763892 A AU1763892 A AU 1763892A AU 17638/92 A AU17638/92 A AU 17638/92A AU 1763892 A AU1763892 A AU 1763892A AU 1763892 A AU1763892 A AU 1763892A
Authority
AU
Australia
Prior art keywords
heparin
periodate
antiproliferative
nac
oxidized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU17638/92A
Other languages
English (en)
Inventor
H. Edward Conrad
Yuchuan Guo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glycomed Inc
Original Assignee
Glycomed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycomed Inc filed Critical Glycomed Inc
Publication of AU1763892A publication Critical patent/AU1763892A/en
Assigned to GLYCOMED INCORPORATED reassignment GLYCOMED INCORPORATED Amend patent request/document other than specification (104) Assignors: GLYCOMED INCORPORATED
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Materials Engineering (AREA)
  • Hematology (AREA)
  • Polymers & Plastics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU17638/92A 1991-03-29 1992-03-27 New non-anticoagulant heparin derivatives Abandoned AU1763892A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US753299 1985-07-10
US67740691A 1991-03-29 1991-03-29
US677406 1991-03-29
US07/753,299 US5280016A (en) 1991-03-29 1991-09-03 Non-anticoagulant heparin derivatives

Publications (1)

Publication Number Publication Date
AU1763892A true AU1763892A (en) 1992-11-02

Family

ID=27101784

Family Applications (1)

Application Number Title Priority Date Filing Date
AU17638/92A Abandoned AU1763892A (en) 1991-03-29 1992-03-27 New non-anticoagulant heparin derivatives

Country Status (7)

Country Link
US (1) US5280016A (enExample)
EP (1) EP0577756A1 (enExample)
JP (1) JPH06506685A (enExample)
AU (1) AU1763892A (enExample)
CA (1) CA2107362A1 (enExample)
NO (1) NO933470L (enExample)
WO (1) WO1992017187A1 (enExample)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811447A (en) * 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) * 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5958883A (en) * 1992-09-23 1999-09-28 Board Of Regents Of The University Of Washington Office Of Technology Animal models of human amyloidoses
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US5770609A (en) * 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6306421B1 (en) 1992-09-25 2001-10-23 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6395494B1 (en) 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
AU5442594A (en) * 1992-10-13 1994-05-09 Virginia Commonwealth University Use of non-anticoagulant heparin for treating ischemia/reperfusion injury
EP0601417A3 (de) * 1992-12-11 1998-07-01 Hoechst Aktiengesellschaft Physiologisch verträglicher und physiologisch abbaubarer, Kohlenhydratrezeptorblocker auf Polymerbasis, ein Verfahren zu seiner Herstellung und seine Verwendung
US5696100A (en) * 1992-12-22 1997-12-09 Glycomed Incorporated Method for controlling O-desulfation of heparin and compositions produced thereby
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5595722A (en) * 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
US6663881B2 (en) * 1993-01-28 2003-12-16 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
ES2355184T3 (es) * 1993-01-28 2011-03-23 Boston Scientific Limited Inhibidores terapéuticos de células de músculo liso vascular.
WO1994026303A1 (en) * 1993-05-13 1994-11-24 Neorx Corporation Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
IT1264709B1 (it) * 1993-07-12 1996-10-04 Italfarmaco Spa Derivati eparinici ad attivita' antimetastatica
JPH09512822A (ja) * 1994-05-06 1997-12-22 グリコメド・インコーポレイテッド Ｏ−脱硫酸化ヘパリン誘導体とその製造法および使用
US5665591A (en) * 1994-12-06 1997-09-09 Trustees Of Boston University Regulation of smooth muscle cell proliferation
US20030083733A1 (en) * 1997-10-10 2003-05-01 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5744457A (en) * 1995-03-31 1998-04-28 Hamilton Civic Hospitals Research Development Inc. Compositions and methods for inhibiting thrombogenesis
US6001820A (en) * 1995-03-31 1999-12-14 Hamilton Civic Hospitals Research Development Inc. Compositions and methods for inhibiting thrombogenesis
US5763427A (en) * 1995-03-31 1998-06-09 Hamilton Civic Hospitals Research Development Inc. Compositions and methods for inhibiting thrombogenesis
US6099562A (en) * 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US5837313A (en) * 1995-04-19 1998-11-17 Schneider (Usa) Inc Drug release stent coating process
US20020091433A1 (en) * 1995-04-19 2002-07-11 Ni Ding Drug release coated stent
CA2223595C (en) * 1995-06-07 2008-08-05 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
DK0835115T3 (da) * 1995-06-30 2004-08-02 Zymogenetics Inc 4-(2-(N-2-carboxamidoindo)aminoethyl)-benzensulfonamider eller -sulfonylurinstoffer som PDGF-antagonister
US6562781B1 (en) * 1995-11-30 2003-05-13 Hamilton Civic Hospitals Research Development Inc. Glycosaminoglycan-antithrombin III/heparin cofactor II conjugates
US7045585B2 (en) * 1995-11-30 2006-05-16 Hamilton Civic Hospital Research Development Inc. Methods of coating a device using anti-thrombin heparin
US6491965B1 (en) 1995-11-30 2002-12-10 Hamilton Civic Hospitals Research Development, Inc. Medical device comprising glycosaminoglycan-antithrombin III/heparin cofactor II conjugates
US5767269A (en) * 1996-10-01 1998-06-16 Hamilton Civic Hospitals Research Development Inc. Processes for the preparation of low-affinity, low molecular weight heparins useful as antithrombotics
EP1033375A4 (en) * 1997-11-20 2002-04-24 Ikuo Yamashina MODIFICATION OF LOW MOLECULAR MASS HEPARIN AND REMEDY FOR SKIN Ulcer
US6498246B1 (en) * 1998-02-26 2002-12-24 Seikagaku Corporation Glycosaminoglycan derivatives and processes for preparing same
JP4633223B2 (ja) * 1999-03-31 2011-02-16 生化学工業株式会社 血管内皮細胞増殖因子依存性血管内皮細胞増殖の抑制剤
CN1371391A (zh) * 1999-06-30 2002-09-25 汉密尔顿市医院研究发展有限公司 抑制凝血相关凝血因子的肝素成分
JP2001163932A (ja) * 1999-10-27 2001-06-19 Novartis Ag 材料表面を改質する方法
IT1316986B1 (it) * 2000-01-25 2003-05-26 Sigma Tau Ind Farmaceuti Derivati glicosamminoglicani parzialmente desolfatati nonanticoagulanti ad attivita' antiangiogenica.
US7781416B2 (en) * 2000-01-25 2010-08-24 Sigma-Tau Research Switzerland S.A. Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect
US20080139503A1 (en) * 2000-01-25 2008-06-12 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect
MXPA03001986A (es) * 2000-09-08 2004-03-19 Hamilton Civic Hospitals Res Composiciones antitromboticas.
US6613083B2 (en) * 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
SE521676C2 (sv) 2002-01-02 2003-11-25 Dilafor Ab Användning av glykosaminoglykaner för prevention och behandling av värksvaghet vid fullgången graviditet
JP2006501815A (ja) * 2002-04-25 2006-01-19 モメンタ ファーマシューティカルズ インコーポレイテッド 粘膜送達のための方法および製品
US8071569B2 (en) * 2002-09-20 2011-12-06 Mousa Shaker A Oxidized heparin fractions and their use in inhibiting angiogenesis
EP1667633A4 (en) * 2003-10-01 2008-10-08 Momenta Pharmaceuticals Inc POLYSACCHARIDE FOR THE PULMONARY DELIVERY OF ACTIVE SUBSTANCES
WO2007019554A2 (en) * 2005-08-08 2007-02-15 Momenta Pharmaceuticals, Inc. Polysaccharides for delivery of active agents
US8569262B2 (en) 2007-11-02 2013-10-29 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
US8592393B2 (en) 2007-11-02 2013-11-26 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
EP2205642B1 (en) 2007-11-02 2016-01-27 Momenta Pharmaceuticals, Inc. Non-anticoagulant polysaccharide compositions
US20090130017A1 (en) * 2007-11-19 2009-05-21 Searete Llc Targeted short-lived drug delivery
CA2795360A1 (en) 2010-04-16 2011-10-20 Momenta Pharmaceuticals, Inc. Tissue targeting
CN103096870B (zh) 2010-06-17 2017-04-19 动量制药公司 调节毛发生长的方法和组合物
EP2484775A1 (de) 2011-02-07 2012-08-08 Siemens Healthcare Diagnostics Products GmbH Heparin-insensitives Verfahren zur Bestimmung von direkten Gerinnungsfaktorinhibitoren
HUE036523T2 (hu) 2011-12-19 2018-07-30 Dilafor Ab Nem anti-koagulatív glikózaminoglikánok ismétlõdõ diszacharid egységgel és ezek gyógyászati alkalmazása
WO2013095215A1 (en) * 2011-12-19 2013-06-27 Dilaforette Ab Low anticoagulant heparins
JP2016520613A (ja) 2013-05-28 2016-07-14 モメンタ ファーマシューティカルズ インコーポレイテッド 薬学的組成物
CN103408677A (zh) * 2013-08-29 2013-11-27 深圳市海普瑞药业股份有限公司 一种抑制细胞增殖的高碘酸氧化的硫酸乙酰肝素
EP3997238A1 (en) 2019-07-09 2022-05-18 Optimvia, LLC Methods for synthesizing anticoagulant polysaccharides
GB202217216D0 (en) * 2022-11-17 2023-01-04 Bhogal Pervinder Singh Preparation of medium molecular weight heparin
WO2025106117A1 (en) * 2023-11-17 2025-05-22 Glycos Biomedical Ltd. Medium molecular weight heparin

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE620906A (enExample) *
US3135660A (en) * 1956-11-09 1964-06-02 Riker Laboratories Inc Method for purifying sulfated carbohydrates with oxidizing agents
IT1195497B (it) * 1983-03-08 1988-10-19 Opocrin Spa Procedimento per la preparazione di frazioni oligosaccaridiche dotate di proprieta' farmacologiche per degradazione chimica di eparina
DE3519011A1 (de) * 1985-05-25 1986-11-27 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung eines materials zur affinitaetschromatographie
US4883751A (en) * 1986-05-28 1989-11-28 New York University Specific immunoassay for heparin
AR243204A1 (es) * 1986-11-21 1993-07-30 Ajorca Sa Un metodo para la depolimerizacion quimica de polisacaridos.
FR2614026B1 (fr) * 1987-04-16 1992-04-17 Sanofi Sa Heparines de bas poids moleculaire, a structure reguliere, leur preparation et leurs applications biologiques
US5032679A (en) * 1988-12-15 1991-07-16 Glycomed, Inc. Heparin fragments as inhibitors of smooth muscle cell proliferation

Also Published As

Publication number Publication date
JPH06506685A (ja) 1994-07-28
WO1992017187A1 (en) 1992-10-15
CA2107362A1 (en) 1992-09-30
US5280016A (en) 1994-01-18
NO933470D0 (no) 1993-09-28
EP0577756A1 (en) 1994-01-12
EP0577756A4 (enExample) 1994-02-09
NO933470L (no) 1993-10-19

Similar Documents

Publication Publication Date Title
US5280016A (en) Non-anticoagulant heparin derivatives
US5250519A (en) Non-anticoagulant heparin derivatives
US5032679A (en) Heparin fragments as inhibitors of smooth muscle cell proliferation
US5380716A (en) Sulfated polysaccharides as inhibitors of smooth muscle cell proliferation
US5696100A (en) Method for controlling O-desulfation of heparin and compositions produced thereby
US5795875A (en) Therapeutic methods of using O-desulfated heparin derivatives
EP0983304B1 (en) Dermatan disulfate, an inhibitor of thrombin generation and complement activation
US5013724A (en) Process for the sulfation of glycosaminoglycans, the sulfated glycosaminoglycans and their biological applications
WO1996006867A9 (en) Method for controlling o-desulfation of heparin and compositions produced thereby
WO1994014851A1 (en) Method for controlling o-desulfation of heparin and compositions produced thereby
US5583121A (en) Non-anticoagulant chemically modified heparinoids for treating hypovolemic shock and related shock syndromes
WO1992018546A1 (en) Sulfated polysaccharides as inhibitors of smooth muscle cell proliferation
WO1994008595A1 (en) Use of non-anticoagulant heparin for treating ischemia/reperfusion injury
Klauser et al. Antithrombotic and anticoagulant properties of synthetic polyanions: sulfated bis-aldonic acid amides.
WO1992017506A1 (en) MODULATION OF tPA ACTIVITY BY HEPARIN FRAGMENTS